{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:06:25Z","timestamp":1789657585136,"version":"4.0.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004319","name":"Shin Kong Wu Ho-Su Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Endocrine diagnoses newly recorded after immune checkpoint inhibitor (ICI) initiation may be associated with subsequent outcomes, but time-dependent bias and the limitations of diagnosis-code attribution complicate interpretation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective 180-day landmark cohort study using a federated electronic health record network. Patients with non\u2013small-cell lung cancer (NSCLC) initiating ICI were classified according to the presence or absence of a newly recorded qualifying thyroid, pituitary, or adrenal diagnosis during days 1\u2013180 after first ICI. Both cohorts excluded qualifying endocrine diagnoses during days \u2212365 to \u22121 and required a recorded visit during months 5\u20136. After 1:1 propensity-score matching, 7,696 patients were included in each group. Outcomes were assessed from day 181.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Newly recorded endocrine diagnoses were associated with lower subsequent mortality (hazard ratio [HR], 0.782; 95% confidence interval [CI], 0.745\u20130.821; P &amp;lt; 0.0001) and a lower hazard of first recorded prespecified subsequent systemic therapy or death in an independently matched analysis (HR, 0.849; 95% CI, 0.773\u20130.934; P\u00a0=\u00a00.0007). Exploratory severe infection (HR, 1.255; 95% CI, 1.151\u20131.369) and healthcare utilization (HR, 1.055; 95% CI, 1.013\u20131.099) outcomes occurred more frequently in the exposed group. Findings were directionally consistent across subgroup and sensitivity analyses, including a repeat-code definition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients satisfying the 180-day landmark and observability criteria, newly recorded endocrine diagnoses after ICI initiation were associated with lower subsequent mortality. This association is conditional on the specified landmark and observability criteria and does not establish ICI attribution, causality, or prediction of comparative treatment benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1957383","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:32:32Z","timestamp":1789655552000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Early endocrine diagnoses and subsequent survival after immune checkpoint inhibitor initiation in non-small cell lung cancer: a 180-day landmark cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Shih-Sen","family":"Lin","sequence":"first","affiliation":[{"name":"Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University","place":["Taipei, Taiwan"]},{"name":"Division of Chest Medicine, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital","place":["Taipei, Taiwan"]},{"name":"Clinical Trial Center, Department of Research, Shin Kong Wu Ho-Su Memorial Hospital","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Sung","family":"Hsu","sequence":"additional","affiliation":[{"name":"Division of Chest Medicine, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Chi","family":"Lai","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Fang","family":"Liu","sequence":"additional","affiliation":[{"name":"Translational Medicine Center, Department of Research, Shin Kong Wu Ho-Su Memorial Hospital","place":["Taipei, Taiwan"]},{"name":"School of Oral Hygiene, College of Oral Medicine, Taipei Medical University","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Pin","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital","place":["Taipei, Taiwan"]},{"name":"Graduate Institute of Human Resource and Knowledge Management, National Kaohsiung Normal University","place":["Kaohsiung, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: A prospective cohort study","volume":"12","author":"Teraoka","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2805-3","article-title":"Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: Long-term outcomes from a multi-institutional analysis","volume":"145","author":"Ricciuti","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.10.002","article-title":"Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer","volume":"20","author":"Grangeon","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.607531","article-title":"Immune-related adverse events and their association with the effectiveness of PD-1\/PD-L1 inhibitors in non-small cell lung cancer: A real-world study from China","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7711","article-title":"Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: Pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials","volume":"9","author":"Socinski","year":"2023","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0063","article-title":"Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center","volume":"6","author":"Lisberg","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1375642","article-title":"Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer","volume":"7","author":"Kim","year":"2017","journal-title":"Oncoimmunology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02802-6","article-title":"Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: An original cohort study","volume":"70","author":"Thuillier","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107296","article-title":"Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer","volume":"91","author":"Zhou","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both Malignant melanoma and non-small cell lung carcinoma: A prospective study","volume":"8","author":"Kobayashi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: New-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: Example using statins for preventing progression of diabetes","volume":"340","author":"L\u00e9vesque","year":"2010","journal-title":"BMJ"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.110.957951","article-title":"Landmark analysis at the 25-year landmark point","volume":"4","author":"Dafni","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.18.00155","article-title":"An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non-small-cell lung cancer","volume":"3","author":"Stewart","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.20.00125","article-title":"Comparisons of real-world time-to-event end points in oncology research","volume":"5","author":"Walker","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.17547","article-title":"Correlation between surrogate end points and overall survival in a multi-institutional clinicogenomic cohort of patients with non-small cell lung or colorectal cancer","volume":"4","author":"Kehl","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70198","article-title":"TriNetX Dataworks-USA: Overview of a multi-purpose, de-identified, federated electronic health record real-world data and analytics network and comparison to the US census","volume":"34","author":"Stein","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1957383\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:32:34Z","timestamp":1789655554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1957383\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":32,"alternative-id":["10.3389\/fonc.2026.1957383"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1957383","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"1957383"}}